Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 58Squamous Cell Carcinoma of Head and Neck 57Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

enzalutamide 4cabazitaxel 3Docetaxel 3Prednisone 2talazoparib 1rucaparib 1pembrolizumab 1olaparib 1Zuclomiphene 1XRP6258 1Standard of Care 1Radiosurgery 1Positron Emission Tomography Computed Tomography 1LY3023414 1Injections 1Carboplatin 1Abituzumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Prostate Cancer Metastatic × Docetaxel × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

NCT04603833 2021-02-21

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
150 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed
63 enrolled 13 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡